Chris Bardon, MD, MBA

Dr. Christiana (Chris) Bardon is Managing Partner of MPM BioImpact and leads the firm’s public market investing as portfolio manager for BioImpact Equities and the Oncology Impact Funds.

Previously, Chris was a health care analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM BioImpact. She currently serves as an Executive Fellow at the Harvard Business School, on the Harvard Medical School Board of Fellows, and is a Trustee of the American Association for Cancer Research Foundation.

Chris earned her M.D. magna cum laude from Harvard Medical School and her M.B.A. from Harvard Business School. While at Harvard Medical School, she was the recipient of a Howard Hughes fellowship, and she completed her residency in Internal Medicine at the Brigham and Women’s Hospital at Harvard Medical School. She received her M.S./B.S. from the Massachusetts Institute of Technology.

Ryan Beltramini, MBA

Ryan Beltramini is Vice President of Global Business Development at Novo Nordisk, where he leads strategic partnerships, licensing, and external innovation initiatives across the biotechnology portfolio. He joined Novo Nordisk in 2021 following senior business development roles at Biogen, Genomatica, and Sanofi Genzyme, where he focused on advancing collaborations and transformative growth opportunities.

Earlier in his career, Mr. Beltramini served as a U.S. Army officer.

He holds an MBA from Harvard Business School and a B.S. from the United States Military Academy at West Point.

Bradley King, JD

Bradley S. King is a Partner in the Mergers & Acquisitions Group at Sullivan & Cromwell LLP, where he advises clients on complex transactions, with a particular focus on the life sciences sector. His practice spans public and private M&A, joint ventures, strategic collaborations, and corporate governance matters.

Mr. King has represented leading pharmaceutical, biotechnology, and medical device companies, as well as financial sponsors investing in healthcare innovation. His experience also includes advising boards of directors on shareholder activism and other strategic situations. Mr. King was named a “Rising Star – Life Sciences” by Law360 in 2023.

Mr. King earned a J.D. from Harvard Law School and a B.A. from the University of Western Ontario.

Sam Murphy, PhD

Sam Murphy is currently CEO of SalubrisBio and has worked at SalubrisBio since 2017. Prior to joining SalubrisBio, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, and a Board Observer at Mercator Medsystems. Sam was previously Board Director at MedAlliance SA (acquired for up to $1.1B by Cordis) and Viracta Therapeutics (public by reverse merger VIRX). He is an author of >20 peer-reviewed publications and an inventor on several issued patents.